Business Wire

VA-ALVOTECH

11.5.2021 16:25:07 CEST | Business Wire | Press release

Share
Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.

Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold as Humira. Humira is the highest grossing prescription drug in the United States with over $16 billion in sales in 2020 (nearly $20Bn globally).

Alvotech has developed a biosimilar (analogous to a generic) of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain-free drug. The company is also developing AVT02 as an interchangeable product and it expects results from its ongoing interchangeability study in Q2 of this year. AVT02 could save U.S. taxpayers and the overall healthcare system $8-10 billion annually.

“Our new product will be a gamechanger that will provide consumers who are suffering from chronic pain with significant savings, and we look forward to bringing this drug onto the market as soon as possible,” said Alvotech Founder and Chairman Robert Wessman .

As alleged in court today, AbbVie seeks to overwhelm Alvotech with 60+ patent claims of questionable validity in order to keep its closest competitor off the market, a tactic it has long used against other competitors. At stake are billions of dollars of cost to the U.S. healthcare system, which is largely driven by AbbVie’s significant price increases that its Humira monopoly makes possible. Later this month, AbbVie will face questions from Congress about whether the company improperly suppresses competition in order to maintain their monopoly.

As alleged in the filing, AbbVie has taken several improper steps to inflate its patent portfolio, specifically:

  • patenting purported inventions that it does not use in the production of Humira;
  • seeking multiple patents on the same invention but as part of different patent families in a manner designed to cause confusion;
  • obtaining patents through inequitable conduct;
  • by seeking patents that cover Humira already in the prior art; and
  • obtaining patents on purported inventions that AbbVie did not invent.

Today, affordable biosimilars to Humira are available across Europe and in Japan, Canada and Australia. The settlement agreements that allowed launches in 2018 of biosimilars in Europe were done to delay launches of similar products in the U.S., thus allowing AbbVie the ability to maintain and even increase prices on the U.S. consumer and taxpayer.

As pointed out in Alvotech’s lawsuit, AbbVie did not invent adalimumab or the subject matter of the original patents surrounding adalimumab and its use, instead acquiring them from German BASF AG. Nevertheless, despite those original patents expiring in 2016, AbbVie has been able to extend its monopoly to 2023 and beyond by deliberately seeking to block legitimate competition.

In 2010, AbbVie developed and tested a less-painful and higher-concentration version of Humira that was as a 100 mg/ml formulation, which the FDA approved in 2015. Yet the company waited nearly three years before bringing this new formulation to the public, a strategic move meant to entrench their control over the market and hobble the competition. Alvotech has developed and is seeking interchangeability for the less-painful, high-concentration version of Humira, which will offer patients the treatment at a more affordable price point.

Furthermore, AbbVie successfully sought and obtained over 100 additional patents of dubious validity that extended its Humira monopoly beyond 2016. Through settlements reached with their competitors, other biosimilars will not enter the market until 2023.

In just the last four years, since its monopoly should have run its course, AbbVie has reported selling over $75 billion worth of Humira and is forecasted to make an additional nearly $40 billion through 2022.

As alleged in today’s filing, this strategy has been called a “minefield of IP” by those in AbbVie’s leadership, meaning the company will engage in endless litigation not to protect innovation but to make challenges to its patent claims cost- and resource-prohibitive for competitors.

About Alvotech

Alvotech is a multinational biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets. We are specialists in biotechnology, seeking to be a global leader in the biosimilar space by delivering high quality, cost-competitive products and services to our partners and to patients worldwide. Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar products. Alvotech’s shareholder base includes, among others, Aztiq Pharma, led by founder and Chairman Mr. Robert Wessman, Fuji Pharma from Japan, Shinhan from Korea, Baxter Healthcare SA, YAS Holdings, ATHOS (Strüngmann Family Office), CVC Capital Partners and Temasek from Singapore.

Alvotech‘s initial pipeline contains several monoclonal-antibody and fusion-protein biosimilar candidates aimed at treating autoimmunity, oncology and inflammatory conditions to improve quality of life for patients around the world. For more information, please visit our website, www.alvotech.com or follow us on LinkedIn , Twitter and Facebook.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 09:00:00 CET | Press release

New K2 division launches a modern, data-driven broking house dedicated to the delegated authority sector. Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents.

Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 08:00:00 CET | Press release

Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu

RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 07:00:00 CET | Press release

RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co

Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 07:00:00 CET | Press release

Pilot completed with DBS and Franklin Templeton via Ant’s WhaleRTP platformWhitepaper launched detailing Whale Orchestration Protocol framework and its development under BLOOM Field GuideSolution achieves Singapore’s first successful cross-asset interoperability between tokenised deposits and tokenised money market funds Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and token

NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 06:30:00 CET | Press release

NETS becomes the first national payment rail to join Ant International’s Agentic Mobile ProtocolNETS and Ant International’s MOU signing signals commitment to deepen the companies’ long-standing collaboration since 2023The partnership aims to deliver comprehensive AI-native merchant solutions to expand reach and lift operational efficiency Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye